Astrazeneca Pharma India Ltd share price logo

Astrazeneca Pharma India Ltd (ASTRAZEN)

₹7081.70.2%

bell
Get free price alerts. Set up your Free investment account to get Live Prices.
Overview
News
Financials
Q1 2024 Results
Technicals

Performance

  • Day's Low

    Day's High

    ₹6,875.1
    ₹7,189
  • 52 Week's Low

    52 Week's High

    ₹3,749.8
    ₹7,572.2
1 Month Return+ 11.87 %
3 Month Return+ 33.73 %
1 Year Return+ 87.47 %
Previous Close₹7,067.60
Open₹7,099.70
Volume1.18L
Upper Circuit-
Lower Circuit-
Market Cap₹17,669.00Cr

Key Statistics

P/E Ratio0
PEG Ratio0
Market Cap₹17,669.00 Cr
P/B Ratio18.68
EPS0

Mutual Fund Holdings

Funds HoldingsPrev. 6M
Nippon India Small Cap Fund - Direct Plan - Growth PlanNippon India Small Cap Fund - Direct Plan - Growth Plan0.73%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct GrowthICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth2.4%
ICICI Prudential Smallcap Fund Direct Plan GrowthICICI Prudential Smallcap Fund Direct Plan Growth0.92%
ICICI Prudential Innovation Fund Direct GrowthICICI Prudential Innovation Fund Direct Growth1.07%
Nippon India Pharma Fund - Direct Plan - Growth PlanNippon India Pharma Fund - Direct Plan - Growth Plan0.54%

Company Information

AstraZeneca Pharma India Limited (APIL) was incorporated on the 11th of July 1979 and is a subsidiary of AstraZeneca Pharmaceuticals AB Sweden, which is an indirect subsidiary of AstraZeneca Plc. It is engaged in manufacture, distribution and marketing of pharmaceutical products in therapy areas such as Onocology, Alimentary Metabolism, Cardio Vascular, Renal Diabetes, Respiratory and Oncology. The company suffered a performance setback due to supply stabilization in 2012, following which the current year witnessed series of regulatory interventions in the Indian Pharmaceutical Market covering 348 medicines including 15 SKUs across 8 brands of the company listed on the National List of Essential Medicines (NLEM). During the year, APIL introduced Arimidex, an Oncology product for the management of breast cancer and decided to make its Astrazeneca India’s RD as a part of its global RD organisation. In 2013-14, the market share of drug brand Brilinta (Ticagrelor) which provides cardiologists with a new and effective treatment to help reduce the rate of heart attack and cardiovascular deaths grew from 1.4 MAT March 2013 to 6.7 MAT March 2014. For the FY 2013-14, the company experienced a range of patient price reduction of 452 and an average price reduction of 30. In 2015-16, key growth brands of APIL such as Brilinta, Forxiga, Onglyza, Kombiglyze, Symbicort witnessed robust growth and diabetes portfolio grew by 74 post acquisition from Bristol MyersSquibb. Meanwhile, Meronem became the company’s first brand to cross the Rs. 100 crore sales milestone. The company entered into three Distribution Services Agreements with Dr. Reddy's Laboratories, Sun Pharma for Ticagrelor and Diabetes treatments, while APIL, Dr. Reddy's Laboratories and Sun Pharma copromote market and distributed Saxagliptin, Dapagliflozin and Ticagrelor under different brand names in Indian markets. During 2017-18, the company aligned its portfolio to AstraZeneca's Global therapeutic focus and introduced Xigduo, a fixed dose combination drug to improve glycemic control for type 2 diabetes mellitus. In 2020-21, the company launched Lynparza, Calquence Acalabrutinib and Benralizumab

Share Price: ₹7081.70 per share as on 24 Jul, 2024 04:01 PM
Market Capitalisation: ₹17,669.00Cr as of today
Listing date: 30 Jul, 1998
Chairperson Name: Narayan K Seshadri
OrganisationAstrazeneca Pharma India Ltd
HeadquartersBangalore
IndustryPharmaceuticals
E-voting on sharesClick here to vote

Key events for Astrazeneca Pharma India Ltd

  • Customs Duty Exemption Boosts AstraZeneca Pharma India - 24 Jul, 2024

    AstraZeneca Pharma India is set to benefit from the exemption of customs duties on three key cancer drugs in the Union Budget 2024-25. The move could increase market share and sales for the company, with shares rallying 13% to Rs 7064.65 on July 23, 2024.

  • Union Budget Boosts Astrazeneca Stock - 23 Jul, 2024

    Astrazeneca Pharma India Ltd saw a surge in trading volume and a 12.14% rise in stock price following the Union Budget's full exemption of custom duties on three cancer drugs, including those produced by Astrazeneca. The move is expected to benefit patients and boost sales.

  • Astrazeneca India to Expand GITC; Stock Volume Surges - 04 Jul, 2024

    Astrazeneca India plans to expand its Global Innovation and Technology Centre in Chennai with an investment of ₹250 crore. The company aims to create around 1,300 jobs focused on driving innovation and enhancing efficiency globally. Astrazeneca Pharma India Ltd's stock volume surged by 27.1 times with a gain of 12.37%.

  • AstraZeneca Pharma India to go ex-dividend on July 5th - 30 Jun, 2024

    AstraZeneca Pharma India is set to pay a dividend of ₹24.00 per share on September 6th, but investors who purchase the stock on or after July 5th will not be eligible for the payout. The company paid out 37% of its profit as dividends last year, but an unsustainably high 234% of its free cash flow over the past 12 months, raising concerns about its ability to maintain the dividend.

  • Multinational Pharma Companies Downsizing in India - 27 Jun, 2024

    Most multinational pharma companies, including Astrazeneca Pharma India Ltd, are downsizing in India due to intense competition from domestic companies and lower realizations. These companies have a non-differentiated branded generics portfolio with limited incremental investment, resulting in MNCs losing market share over the years.

Insights on Astrazeneca Pharma India Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, ASTRAZEN has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

  • imgPOSITIVE IMPACT

    FII Holding Up

    img

    Foreign Institutions have increased holdings from 2.74% to 2.79% in Jun 2024 quarter

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 3.75% to 4.97% in Jun 2024 quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, ASTRAZEN stock has moved up by 9.5%

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 75.00% of holdings in Jun 2024 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 127.7% return, outperforming this stock by 24.2%

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 18.48% to 17.20% in Jun 2024 quarter

Company Financials

Value in ₹ crore
2024Y/Y Change
Total Assets
₹1,079.09Cr
↑9.40%
Total Liabilities
₹367.17Cr
↓7.68%
Value in ₹ crore
2024Y/Y Change
Operating Cash Flow
₹27.87Cr
↓52.19%

Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
75%
0.00
Foreign Institutions
2.79%
2.05
Mutual Funds
4.97%
32.55
Retail Investors
17.2%
-6.95
Others
0.04%
21.94

Key Indicators

Earnings and Dividends

  • Astrazeneca Pharma India Ltd Earnings Results

    Astrazeneca Pharma India Ltd’s net profit jumped 128.6% since last year same period to ₹39.48Cr in the Q4 2023-2024. On a quarterly growth basis, Astrazeneca Pharma India Ltd has generated 149.87% jump in its net profits since last 3-months.

    Read More about Earnings Results
  • Astrazeneca Pharma India Ltd Dividends May,2024

    In the quarter ending March 2024, Astrazeneca Pharma India Ltd has declared dividend of ₹24 - translating a dividend yield of 0.57%.

    Read More about Dividends

Technicals Summary

Bearish

Neutral

Bullish

Bullish

Astrazeneca Pharma India Ltd is currently in a Bullish trading position according to technical analysis indicators.

Frequently Asked Questions

  • Get a PAN card.
  • Open a Demat account.
  • Open a Trading account.
  • Link your Demat account to your Trading account.
  • Fund your Trading account.
  • Place an order to buy Astrazeneca Pharma India Ltd shares.

Astrazeneca Pharma India Ltd (ASTRAZEN) share price today is ₹7081.7

Astrazeneca Pharma India Ltd is listed on NSE

Astrazeneca Pharma India Ltd is listed on BSE

  • Today’s highest price of Astrazeneca Pharma India Ltd is ₹7189.
  • Today’s lowest price of Astrazeneca Pharma India Ltd is ₹6875.1.

Today’s traded volume of Astrazeneca Pharma India Ltd(ASTRAZEN) is 1.18L.

Today’s market capitalisation of Astrazeneca Pharma India Ltd(ASTRAZEN) is ₹17669Cr.

Astrazeneca Pharma India Ltd(ASTRAZENPrice
52 Week High
₹7572.2
52 Week Low
₹3749.8

Astrazeneca Pharma India Ltd(ASTRAZEN) share price is ₹7081.7. It is down -6.48% from its 52 Week High price of ₹7572.2

Astrazeneca Pharma India Ltd(ASTRAZEN) share price is ₹7081.7. It is up 88.86% from its 52 Week Low price of ₹3749.8

Astrazeneca Pharma India Ltd(ASTRAZENReturns
1 Day Returns
14.1%
1 Month Returns
11.87%
3 Month Returns
33.73%
1 Year Returns
87.47%